Takeda Pharmaceutical has teamed up with Harrington Discovery Institute to support research into treatments for rare diseases.

Shares in U.K. biotech Synairgen were pummeled today as partner AstraZeneca revealed it was stopping development of its inhaled interferon beta therapy AZD9412.

Novartis will play a bigger role in the marketing of Amgen's migraine drug erenumab, and analysts say the move may reflect reduced sales expectations.

Cancer Research UK has teamed up with the National Cancer Institute to fund work on inhibitors of Ras proteins.

Ionis Pharmaceuticals has enlisted the help of Suzhou Ribo Life Science to help it bring three of its RNA-based drugs to the Chinese market.

Mission Therapeutics and the University of Oxford have landed a Michael J. Fox Foundation grant to fund testing of USP30 inhibitors.

Takeda has unveiled its second microbiome pact in a week to continue its gastrointestinal deal spree.

OncoMed shares tanked after its Celgene-partnered lead asset flunked a phase 2 pancreatic cancer trial and Bayer walked away from two drugs.

Johnson & Johnson has deferred making a decision about whether to drop or commit to Geron’s imetelstat.

Johnson & Johnson has become the latest Big Pharma to turn to PeptiDream for help discovering and optimizing peptide therapeutics.